<DOC>
	<DOCNO>NCT01663103</DOCNO>
	<brief_summary>Risk cardiovascular disease ( CVD ) significantly elevate patient chronic kidney disease ( CKD ) ; however , increase risk partially explain traditional cardiovascular risk factor . Patients CKD exhibit chronic inflammation , key mechanism contribute vascular dysfunction ( i.e. , large elastic artery stiffen endothelial dysfunction ) . Inhibiting inflammation improve vascular dysfunction population characterize chronic inflammation . However , currently unknown reduce inflammation interleukin-1 ( IL-1 ) blocker enhance vascular function CKD patient . Aim 1 ass efficacy IL-1 block rilonacept treat vascular dysfunction patient stage III IV CKD ( estimate glomerular filtration rate 15-60 mL/min/1.73 m2 ) . Aim 2 determine block IL-1 rilonacept also reduce inflammation oxidative stress . These study could shift clinical practice guideline establish novel therapy reduce CVD risk CKD patient require chronic hemodialysis .</brief_summary>
	<brief_title>Interleukin-1 Trap Treat Vascular Dysfunction Chronic Kidney Disease ( CKD )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Age 1880 year CKD stage III IV ( eGFR 4variable Modified Diet Renal Disease ( MDRD ) prediction equation : 1560 mL/min/1.73m2 ; stable renal function past 3 month ) An elevated high sensitivity Creactive protein ( hsCRP ) &gt; 2.0 mg/L &lt; 30 mg/L least 2 consecutive weekly determination Urine protein excretion &lt; 5.0 g/24h estimate spot urine protein/creatinine ratio Ability provide inform consent Patients advance CKD require chronic dialysis Active infection ( chronic acute ( within 3 month ) antibiotic therapy ( w/in 1 mo ) ; history recurrent infection Significant comorbid condition lead investigator conclude life expectancy le 1 year Expected undergo living relate transplant next 6 month History severe congestive heart failure ( i.e. , EF &lt; 35 % ) Hospitalization past month Severe arthritis , lupus , inflammatory bowel disease , asthma disease ( ) medical condition ( ) , opinion investigator , could interfere hsCRP immune function Immunosuppressant agent cyclosporine , tacrolimus , azathioprine , etanercept , infliximab , adalimumab , anakinra longterm oral glucocorticoid take past 12 month Known malignancy HIV , active , chronic hepatitis B evidence HBsAg positive HBsAb negative , hepatitis C positive Woman pregnant , nurse plan become pregnant Body mass index ( BMI ) &gt; 40 kg/m2 Warfarin use ( cytochrome P ( CYP ) 450 substrate narrow therapeutic index ) [ ok participate endothelial cell collection ] Taking medication ( ) interact agent administer experimental session ( e.g. , sildenafil interacts nitroglycerin ) Currently receive plan receive live inactivate vaccine Alcohol dependence abuse Subjects risk tuberculosis ( TB ) . Specifically , subject : Current clinical , radiographic laboratory evidence active TB screening latent TB previously treat A history active TB within last 3 year even treat . A history active TB great 3 year ago unless documentation prior antiTB treatment appropriate duration type . Therapy latent TB complete per local guideline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Interleukin-1</keyword>
	<keyword>Endothelium , Vascular</keyword>
	<keyword>Vascular Stiffness</keyword>
	<keyword>Oxidative Stress</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Endothelial cell</keyword>
</DOC>